Mark A. Demitrack
About Mark A. Demitrack
Mark A. Demitrack is a board-certified psychiatrist with over thirty years of experience in clinical neuroscience research, currently serving as the Senior Vice President and Chief Medical Officer. He has held significant roles in clinical development and medical affairs across various organizations.
Mark A. Demitrack Education and Expertise
Mark A. Demitrack received a BA in Physics from Columbia University and earned his MD from the Robert Wood Johnson Medical School in New Jersey. He completed psychiatry residency training at the University of California-San Francisco and a research fellowship in clinical neuroendocrinology at the National Institute of Mental Health. Demitrack is a board-certified psychiatrist with over thirty years of experience in both academic and industry settings, focusing on clinical neuroscience research.
Mark A. Demitrack Professional Background
Mark A. Demitrack has held various high-level positions in the healthcare and pharmaceutical industries. He served as the Vice President of Clinical Strategy at Roivant Sciences from May 2017 to May 2018. Prior to this, he was the Vice President and Chief Medical Officer of Neuronetics, Inc., from July 2003 to May 2017, where he led the clinical development for the NeuroStar TMS Therapy System. He also held the role of Assistant Vice President for Global Medical Affairs in Neuroscience at Wyeth Pharmaceuticals and was the Medical Director of the New Antidepressant Team at Lilly Research Laboratories, where he was responsible for the initial NDA submission for duloxetine (Cymbalta).
Mark A. Demitrack Academic Contributions
Mark A. Demitrack was a faculty member at the University of Michigan Medical School's Department of Psychiatry. During his tenure, he directed the Michigan Eating Disorders Program and secured federal grant funding for research in the neuroendocrine pathophysiology of eating disorders, chronic fatigue syndrome, and fibromyalgia. He has also published over 100 articles, book chapters, and reviews focusing on mood disorders and related conditions.
Mark A. Demitrack Industry Achievements
Mark A. Demitrack's career is marked by significant achievements in the pharmaceutical and medical device industries. At Neuronetics, Inc., he led the clinical development of the NeuroStar TMS Therapy System for depression treatment. At Lilly Research Laboratories, he guided the registration clinical development and initial NDA submission for the antidepressant duloxetine (Cymbalta). His work has had a profound impact on the development and approval of treatments for mood disorders.
Mark A. Demitrack Professional Affiliations
Mark A. Demitrack is a Fellow of the American Psychiatric Association and a Member of the American College of Neuropsychopharmacology. These affiliations signify his commitment to the field of psychiatry and his ongoing contribution to neuropsychopharmacology research and clinical practice.